Although GLP-1s are showing knock-on benefits for a variety of symptoms and conditions, theres reason for caution
Patients: An oral alternative may improve access and increase willingness to seek treatment
Gruben N, Shiri-Sverdlov R, Koonen DP, Hofker MH
"Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo"
(Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-2) of higher dose 9 mg mazdutide (Innovent R&D Code: IBI362) , a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity
Synjardy and alcohol can be a risky combination